Publications

2024

2023

Effects of (-)-MBP, a novel 5-HT2C agonist and 5-HT2A/2B antagonist/inverse agonist on brain activity: A phMRI study on awake mice

Preeti K. Sathe, Gargi R. Ramdasi, Kaylie Giammatteo, Harvens Beauzile, Shuyue Wang, Heng Zhang, Praveen Kulkarni, Raymond G. Booth, Craig F. Ferris

Conformationally Selective 2-Aminotetralin Ligands Targeting the alpha2A- and alpha2C-Adrenergic Receptors

Nicholas R. Fragola, Brittany M. Brems, Munmun Mukherjee, Meng Cui, and Raymond G. Booth

2022

“Selective” serotonin 5-HT2A receptor antagonists

Austen B. Casey, Meng Cui, Raymond G. Booth, Clinton E. Canal

2021

A new class of 5-HT2A/5-HT2C receptor inverse agonists: Synthesis, molecular modeling, in vitro and in vivo pharmacology of novel 2-aminotetralins

Austen B. Casey, Munmun Mukherjee, Ryan P. McGlynn, Meng Cui, Stephen J. Kohut, Raymond G. Booth

Evaluation of lorcaserin as an anticonvulsant in juvenile Fmr1 knockout mice

Tanishka S. Saraf, Daniel E. Felsing, Jessica L. Armstrong, Raymond G. Booth, Clinton E. Canal

2020

Synthesis of novel 5-substituted-2-aminotetralin analogs: 5-HT1A and 5-HT7 G protein-coupled receptor affinity, 3D-QSAR and molecular modeling

Charles K. Perry, Austen B. Casey, Daniel E. Felsing, Rajender Vemula, Mehreen Zaka, Noah B. Herrington, Meng Cui, Glen E. Kellogg, Clinton E. Canal, Raymond G. Booth

2019

Ligand-directed serotonin 5-HT2C receptor desensitization and sensitization

Daniel E. Felsing, Clinton E. Canal, Raymond G. Booth

2017

2015

An Orally Active Phenylaminotetralin-Chemotype Serotonin 5-HT7 and 5-HT1A Receptor Partial Agonist that Corrects Motor Stereotypy in Mouse Models

Clinton E. Canal, Daniel E. Felsing, Yue Liu, Wanying Zhu, JodiAnne T. Wood, Charles K. Perry, Rajender Vemula, and Raymond G. Booth

Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors

Rajeev Sakhuja, Krishnakanth Kondabolu, Tania Córdova-Sintjago, Sean Travers, Adam S. Vincek, Myong Sang Kim, Khalil A. Abboud, Lijuan Fang, Zhuming Sun, Clinton E. Canal, and Raymond G. Booth

2014

A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses

Clinton E. Canal, Drake Morgan, Daniel Felsing, Krishnakanth Kondabolu, Neil E. Rowland, Kimberly L. Robertson, Rajeev Sakhuja, and Raymond G. Booth

2013

Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications

Drake Morgan, Krishnakanth Kondabolu, Allison Kuipers, Rajeev Sakhuja, Kimberly L. Robertson, Neil E. Rowland, and Raymond G. Booth

2012

2011

Drug discovery targeting human 5-HT(2C) receptors: residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formation

Clinton E. Canal, Tania C. Cordova-Sintjago, Nancy Y. Villa, Li-Juan Fang, and Raymond G. Booth

A novel potential therapeutic avenue for autism: design, synthesis and pharmacophore generation of SSRIs with dual action

Ola M. Ghoneim, Diaa A. Ibrahim, Ibrahim M. El-Deeb, So Ha Lee, and Raymond G. Booth

2009

(1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity

Raymond G. Booth, Lijuan Fang, Yingsu Huang, Andrzej Wilczynski, and Sashikala Sivendran

2008

Effect of (-)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in mice

Neil E. Rowland, Erica M. Crump, Nancy Nguyen, Kimberly Robertson, Zhuming Sun, Raymond G. Booth

Molecular determinants of ligand-directed signaling for the histamine H1 receptor

Raymond G. Booth, L. Fang, A. Wilczynski, S. Sivendren, Z. Sun, S. Travers, M. Bruysters, K. Sansuk, and R. Leurs

2007

2006

2005

2004

Domain swapping in the human histamine H1 receptor

Remko A. Bakker, Guido Dees, Juan J. Carrillo, Raymond G. Booth, Juan F. López-Gimenez, Graeme Milligan, Philip G. Strange, and Rob Leurs

Functional heterogeneity of histamine H(1) receptors

N. H. Moniri and Raymond G. Booth

2002

A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors

Raymond G. Booth, Nader H. Moniri, Remko A. Bakker, Neepa Y. Choksi, William B. Nix, Henk Timmerman, and Rob Leurs

Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase

David M. Mottola, Jason D. Kilts, Mechelle M. Lewis, Hilary S. Connery, Q. David Walker, Sara R. Jones, Raymond G. Booth, Deborah K. Hyslop, Monford Piercey, R. Mark Wightman, Cindy P. Lawler, David E. Nichols, and Richard B. Mailman

2000

1999

1997

Effects of polychlorinated biphenyls (PCBs) on brain tyrosine hydroxylase activity and dopamine synthesis in rats

Neepa Y. Choksi, Prasada Rao S. Kodavanti, Hugh A. Tilson, and Raymond G. Booth 

1995

1-Phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes and related derivatives as ligands for the neuromodulatory sigma 3 receptor: further structure-activity relationships

Steven D. Wyrick, Raymond G. Booth, Andrew M. Myers, Constance E. Owens, Ehren C. Bucholtz, Phillip C. Hooper, Nora S. Kula, Ross J. Baldessarini, and Richard B. Mailman

1994

Conformational analysis, pharmacophore identification, and comparative molecular field analysis of ligands for the neuromodulatory sigma 3 receptor

Andrew M. Myers, Paul S. Charifson, Constance E. Owens, Nora S. Kula, Andrew T. McPhail, Ross J. Baldessarini, Raymond G. Booth, and Steven D. Wyrick

1993

New sigma-like receptor recognized by novel phenylaminotetralins: ligand binding and functional studies

Raymond G. Booth, S D Wyrick, R J Baldessarini, N S Kula, A M Myers, and R B Mailman

Synthesis and pharmacological evaluation of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for a novel receptor with sigma-like neuromodulatory activity

Steven D. Wyrick, Raymond G. Booth, Andrew M. Myers, Constance E. Owens, Nora S. Kula, Ross J. Baldessarini, Andrew T. McPhail, and Richard B. Mailman

1991

Dopamine D1 autoreceptor function: possible expression in developing rat prefrontal cortex and striatum

Martin H. Teicher, Amelia L. Gallitano, Harris A. Gelbard, Henriette K. Evans, Elda R. Marsh, Raymond G. Booth, and Ross J. Baldessarini

1990

In vivo intracerebral microdialysis studies in rats of MPP+ analogues and related charged species

Hans Rollema, E. Anne Johnson, Raymond G. Booth, Patricia Caldera, Peter Lampen, Stephen K. Youngster, Anthony J. Trevor, Noreen Naiman, and Neal Castagnoli Jr.

Presynaptic inhibition of dopamine synthesis in rat striatal tissue by enantiomeric mono- and dihydroxyaporphines

Raymond G. Booth, R J Baldessarini, N S Kula, Y Gao, R Zong, and J L Neumeyer

1989

1-methyl-4-phenylpyridinium (MPP+) analogs: in vivo neurotoxicity and inhibition of striatal synaptosomal dopamine uptake

E.Anne Johnson, Ellen Y. Wu, Hans Rollema, Raymond G. Booth, Anthony J. Trevor, and Neal Castagnoli Jr.

Studies on semirigid tricyclic analogues of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Raymond G. Booth, Anthony Trevor, Thomas P. Singer, and Neal Castagnoli Jr.

1988

Selective inhibition of Leishmania dihydrofolate reductase and Leishmania growth by 5-benzyl-2,4-diaminopyrimidines

Worachart Sirawaraporn, Rachada Sertsrivanich, Raymond G. Booth, Corwin Hansch, R.A. Neal, and Daniel V. Santi

1987

Inhibition of NADH oxidation by pyridine derivatives

Rona R. Ramsay, Kathleen A. McKeown, Elizabeth Anne Johnson, Raymond G. Booth, and Thomas P. Singer